See the DrugPatentWatch profile for Vyndaqel
What is Vyndaqel (tafamidis) and what would a “generic release” mean?
Vyndaqel is the brand name for tafamidis (used in transthyretin amyloid cardiomyopathy). A “generic release date” usually refers to when an FDA-approved generic or biosimilar becomes available in the US, or when exclusivity around the brand expires and other manufacturers can launch an approved product. However, a specific generic launch date is not provided in the supplied information, so it can’t be confirmed here.
When are tafamidis generics expected to launch?
To identify the actual “Vyndaqel generic release date,” you typically need one of these:
- The FDA Orange Book entry for tafamidis, including patent and exclusivity information, and any “expiration” dates tied to marketing exclusivity.
- A later FDA action or approval announcement for an abbreviated new drug application (ANDA), if a generic has already been approved.
Without those dates or an Orange Book entry in the provided material, I can’t state a release date accurately.
How to find the exact release date yourself (fast)
Search the FDA system for the most precise dates:
- Look up the product in the FDA Orange Book (tafamidis/brand: Vyndaqel) and check:
- “Patent Expiration” dates
- “Exclusivity” expiration dates
- Any listed “launch” or approval-related milestones tied to competitors
If you share the exact product listing (or the Orange Book “application number”/patent list) you’re using, I can help interpret which date actually controls generic entry and what it means for launch timing.
Is Vyndaqel ever replaced by a different tafamidis brand?
Some patients see tafamidis marketed under different brand names depending on formulation/strength and country availability. People searching for a “generic release” sometimes actually want the time when a lower-cost tafamidis option (brand-to-generic or brand-to-brand switch) becomes available.
If you tell me your country (US vs. EU vs. UK) and whether you mean Vyndaqel specifically or tafamidis broadly, I can narrow the right “release” concept.
What I need to give you the real date
Send either:
- Your country/market (e.g., US), plus the dosage form/strength you mean, or
- A link or screenshot text from the FDA Orange Book entry for Vyndaqel (tafamidis)
Then I can translate the patent/exclusivity timeline into the closest answer to “Vyndaqel generic release date” based strictly on those listed expiration points.